USA flag logo/image

An Official Website of the United States Government

Characterization of antitumor auto-antibodies using combinatorial peptide…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43CA168014
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA09-189
Small Business Information
PharmaSeq, Inc.
11 Deer Park Dr. Suite 104 Monmouth Jct., NJ 08852-1923
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Characterization of antitumor auto-antibodies using combinatorial peptide librari
Agency: HHS
Contract: 1R43CA168014-01A1
Award Amount: $272,360.00
 

Abstract:

DESCRIPTION (provided by applicant): The development of circulating auto-antibodies to tumor-associated antigens (TAAs) has been observed at early cancer stages. TAA auto-antibodies are attractive as diagnostic markers because they are stable and persistent in cancerous conditions yet minimally present in normal individuals and most noncancerous conditions. However, the identification of auto-antibodies specific for a particular type of cancer is complicated due to the relatively low-abundance of an individual antibody within the complexity of the human proteome. The purpose of the present project is to develop an approach to detect auto-antibodies to tumor-associated antigens using an encoded combinatorial peptide library synthesized on PharmaSeq's light-activated radio-frequency p-Chips. Preparing the combinatorial library on the p-Chip platform serves two purposes: 1) to enrich for low-abundance proteins based on established principles of solid-phase affinity adsorption and 2) to rapidly identify the affinity ligand on each chip based on the encoded ID. The main project goal is to synthesize an RFID-encoded peptide library consisting of several thousands of random tetramers using the split-and-mix method. We will use a high speed fluidics-based analytical instrument previously developed by PharmaSeq to identify p-Chips carrying specific peptides with affinity to human auto- antibodies. In addition we will quantitatively characterize differences in immunoglobulin profiles between early stage ovarian andbreast cancer patient and normal control samples. The methods developed will enable, for the first time, a true encoded one- particle-one-compound high throughput library synthesis and screening method that is capable of direct translation as a clinical diagnostic platform. PUBLIC HEALTH RELEVANCE: Auto-antibodies generated against tumor-associated antigens show great potential for the accurate, early diagnosis of cancer but identifying antibodies specific to a particular type of cancer is challenging, requiring a sensitive, high-throughput system that can discriminate key biomarkers against a high protein load. The implementation of an RFID- encoded combinatorial peptide library with PharmaSeq's light-activated p-Chip system will enable the simultaneous enrichment and identification of clinically-relevant biomarkers on a unified, high-throughput platform.

Principal Investigator:

Wlodek Mandecki
732-355-0100
mandecki@pharmaseq.com

Business Contact:

Wlodek Mandecki
732-355-0100
mandecki@pharmaseq.com
Small Business Information at Submission:

PHARMASEQ, INC.
11 DEER PARK DR, STE 104 MONMOUTH JUNCTION, NJ -

EIN/Tax ID: 151043993
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No